The UK and US have forged a landmark bilateral deal that will keep no duties on UK pharmaceutical shipments being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to increase funding on medicines through the public health system. This pledge guarantees that tariffs on these key exports will stay at nothing for a duration of three years.
This development comes after previous threats to hike tariffs on branded pharmaceutical imports, with potential rates discussed reaching double the cost.
"This deal between the Britain strengthens the worldwide climate for new treatments and brings long-overdue fairness to transatlantic medicine commerce," an announcement noted.
Commercial Impact
Medicines represent one of the UK's most significant exports to the US, which is clearly the largest market for leading British pharmaceutical firms.
Export figures reveal that in the one-year period leading up to the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that timeframe.
"This guarantee secures work, stimulates investment and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The deal involves several notable pledges from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds were more than twenty percent.
Recent Tensions
The deal takes place against a protracted tension between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
These tensions were exacerbated by claims that American patients were paying a premium for the equivalent treatments than people in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the last ten years.
